in their recent article in Lancet Oncology, studied adverse effects related to a rela tively new therapeutic modality for local ized prostate cancer: the ablation of prostate tumours using highintensity focused ultrasound (HIFU).
Having previously published the initial results of a phase I/II trial on 20 patients, which reported the shortterm outcomes of 'hemiablation' for a priori unilateral pros tate cancer, 2 they report herein the prelimi nary results of using HIFU to treat a cohort of 42 men with prostate cancer treated focally according to their prostate cancer location, assessed by ultrasonography guided biopsy templates and MRI. They conclude that "focal therapy of individual prostate cancer lesions, whether multi focal or unifocal, leads to low rate of genito urinary side effects and an encouraging rate of early absence of clinically significant prostate cancer".
Without any doubt, tumour ablationparticularly in the prostate-has to be studied, and this therapeutic modality might become a new option within the present armatorium for localized prostate cancer, which currently includes active surveillance protocols, "watchfulwaiting", radiotherapy and surgery. However, this study evaluates a new concept of treat ment-tumour ablation as opposed to whole gland treatment-using a fairly new therapeutic modality, and is not so much interested in demonstrating that the therapeutic protocol is as efficient as radical surgery or radiotherapy in terms of cure, but was instead powered to demon strate that side effects are minimized. In this sense, stating that HIFU "continues to support the proposition that tissue pres ervation leads to functional preservation" looks like a tautology that doesn't need such surgical experimentation, but, in fact, places the patient at risk for incomplete treatment. 3 We are all aware of the prostate cancer conundrum that Willet Whitmore, a former chairman of the department of Urology at Memorial Sloan Kettering Cancer Center in New York, once posed: "Is cure of pros tate cancer possible when it is necessary? Is cure necessary when it is possible?" Thus, either the tumour presents lifethreatening risk characteristics and it should be treated adequately and efficiently, and only later question how side effects can be mini mized, or the tumour is considered to be possibly indolent and the question of active treatment is fundamentally erroneous and perverse.
But beyond this, and without even con sidering the protocol itself and the way end points were assessed, this paper seems to represent a milestone in cancer therapeutic research-to my knowledge, it represents the first attempt to consider a new cancer treatment by analysing adverse effects before efficacy has been fully established. Indeed, it is noticeable that, currently, the results of studies investigating the efficacy of HIFU published in the medical litera ture are particularly contradictory among different teams, probably because thera peutic protocols and evaluation criteria are not yet established and standardized. 
''
Nevertheless, it could be damaging for the medical community and, indeed, for our patients, that researchers might feel free to evaluate and publish studies on any kind of treatment as long as adverse effects are minimal. The risk of such a paradigm shift is to open Pandora's box to studies whose aims are no longer to establish the thera peutic roles of new therapies, and potentially serve only to add more con fusion to the field of localized prostate cancer treatment. 
and compared the morbid ity and oncological outcomes of intensity modulated radiation therapy (IMRT), proton therapy and conformal radiation therapy (CRT). The subsequent identifica tion of condition codes that were likely to be attributable to radiation therapy were used to estimate rates of postradiation gastro intestinal, urinary and erectile dysfunction, as well as hip fractures. Cancer outcomes were approximated using the rates of additional cancer therapy.
The authors documented the extra ordinarily rapid adoption of costly IMRT, which increased in market share from 0.15% to 95.9% between 2000 and 2008. Using propensityscoreadjusted analysis they demonstrated that when compared with CRT, patients undergoing IMRT were less likely to have gastrointestinal morbidity (RR 0.91; 95% CI 0.86-0.96) and to suffer hip fractures (RR 0.78; 95% CI 0.65-0.93) but more likely to experience erectile dys function (RR 1.12; 95% CI 1.03-1.20). Patients who underwent IMRT were also less likely to require additional cancer treat ment (RR 0.81, 95% CI 0.73-0.89). These relative effects, although statistically sig nificant owing to large sample sizes, might only equate to small absolute differences of unknown clinical relevance in the absence of patientreported quality of life measures. For example, a rate of grade ≥2 rectal toxi city of 26% was identified in one highdose CRT prospective trial, 3 but the analysis of Sheets et al. 2 suggests that this toxicity would fall by just 2.3% using IMRT.
The analysis also compared IMRT with proton therapy, which is even more expensive than IMRT, and found no bene fits for proton therapy in terms of either cancer control or toxicity. In fact, IMRT was associated with substantially fewer gastro intestinal adverse events than proton therapy (RR 0.66; 95% CI 0.55-0.79). 2 The strengths of this paper include its large, populationbased cohort, adjustment for baseline comorbidity, and the inclusion of proton therapy for the first time in a direct comparison against the other major forms of prostate cancer radiotherapy. Limitations include those associated with the use of administrative datasets, particu larly biases inherent to treatment selection, and the use of billing codes as proxies for validated questionnaires, which are more reliable measurements of functional out comes such as erectile dysfunction. While the propensity score and instrumental vari able techniques employed are able to control for most bias related to measured covari ates, elimination of bias related to unmeas ured confounders would only be possible through randomization. One such missing confounder is the use of imageguided radi ation therapy. Hitting the intended target is crucial for all radiation therapy, for both cancer control and toxicity avoidance. By not taking this into account, the outcomes of CRT in this study might be confounded by poor target localization.
However, even within the acknowledged limitations of this observational popula tionbased study, it is reasonable to make three main conclusions. First, that IMRT can provide superior cancer control to CRT. Second, that IMRT is associated with a lower rate of gastro intestinal toxicity but a higher incidence of erectile dysfunction when compared to CRT, and finally that proton therapy provides no advantage over IMRT and has considerably higher gastro intestinal toxicity. The superior cancer control of IMRT is unsurprising given that the impetus for this technology came from strong evidence that dose escalation led to considerably improved survival, though at the cost of increased morbidity. 4, 5 Nevertheless, although it is reassuring to see that moresophisticated delivery techniques are associated with reduced gastrointestinal and hip morbidity, it is disappointing to dis cover that those undergoing IMRT are more likely to be diagnosed with erectile dysfunc tion than those who receive CRT. This is presumably due to the higher dose delivered to the nearby neurovascular bundles.
The increased cost associated with the wholesale switch to IMRT was not con sidered in this paper, an issue that is now exacerbated by the growing use of proton therapy and other novel techniques, such as stereotactic radiation, for localized prostate cancer. Furthermore, although it is note worthy that RARP has grown to occupy 61% of the radical prostatectomy market in the USA over the past decade without any level 1 evidence to demonstrate its superior ity, 6 it is even more remarkable that IMRT has grown to occupy 96% of the external beam radiotherapy market without any similar evidence.
Nguyen et al. 7 reported that the cost of IMRT in 2005 was US$31,574 compared to $20,588 for CRT. Similarly, brachy therapy plus IMRT cost $36,795 compared to $26,006 for brachytherapy plus CRT. 7 The cost for minimallyinvasive (robotic) pros tatectomy was more modest at $16,762, which was less than $300 more than the cost of open surgery. Based on these 2005 figures and the 81% adoption of IMRT at that time, Nguyen et al. 7 calculated that the switch to IMRT had added $341 million in costs per annum to the cost associated with CRT. Extrapolation to 2012, in light of the 96% adoption of IMRT in 2008, would clearly add enormously to this figure. At a funda mental philosophical level, these data vin dicate the calls for appropriate comparative '' ...proton therapy provides no advantage over IMRT and has considerably higher gastrointestinal toxicity '' evaluation of new technology, 8 a notion that proton advocates have deemed, quite incredibly, unethical. 9 Another concern is the reported increase in the number of urology practices in the USA that are investing in IMRT technol ogy, and allegations that financial incen tives are driving increased utilization. 10 The impact of adopting integrated prac tice models on practice patterns remains controversial. Regardless, what is clear is that a combination of factors is driving the costs of managing localized prostate cancer to unsustainable levels. These include an ageing population and increasing disease incidence; expensive surgical technol ogy; expensive radiation technology; more emerging technologies; and under utilization of active surveillance as a management option.
There is no doubt that the costs of man aging localized prostate cancer will become a major challenge for healthcare systems in the coming decades, and that comparative effectiveness research must become a pri ority to help inform doctors, patients and funders about the most sustainable strategy to manage these challenges. 
